Bezwoda W R, Bezwoda M A, Seymour L, Dansey R, Ariad S
Department of Medicine, University of Witwatersrand Medical School, Johannesburg, South Africa.
Leuk Lymphoma. 1993 Jul;10(4-5):329-33. doi: 10.3109/10428199309148556.
Forty three patients with relapsed, diffuse aggressive lymphoma (Working Formulation Categories G to J) were treated with a combination chemotherapy regimen consisting of mitoxantrone 10 mg/m2 iv day 1, vincristine 1.4 mg/m2 iv day 1 and 14, prednisolone 50 mg/m2 p.o. days 1-5 and etoposide 100 mg/m2 p.o. days 1-5 of each cycle (NOPE). Fourteen patients (34%) achieved complete remission and another 6/43 (15%) achieved a partial response. Factors which significantly affected response were the presence of early stage, absence of systemic symptoms, non-bulky disease and serum LDH value < 350 IU. Four patients are alive and in complete remission from 25+ to 45+ months after completion of therapy. Duration of response and survival was significantly influenced by the duration of the initial response to first chemotherapy. NOPE is an active and safe treatment regimen with a substantial complete remission rate in patients with relapsed non-Hodgkin's lymphoma.
43例复发的弥漫性侵袭性淋巴瘤（工作分类G至J）患者接受了联合化疗方案治疗，该方案包括：米托蒽醌10mg/m²静脉注射，第1天；长春新碱1.4mg/m²静脉注射，第1天和第14天；泼尼松龙50mg/m²口服，第1至5天；依托泊苷100mg/m²口服，每个周期的第1至5天（NOPE方案）。14例患者（34%）实现完全缓解，另外6/43例（15%）实现部分缓解。显著影响缓解的因素包括疾病处于早期、无全身症状、疾病非大包块型以及血清乳酸脱氢酶值<350IU。4例患者在完成治疗后25+至45+个月仍存活且处于完全缓解状态。缓解期和生存期受首次化疗初始缓解期的显著影响。NOPE方案是一种有效且安全的治疗方案，对于复发的非霍奇金淋巴瘤患者有相当高的完全缓解率。
